Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Capricor Therapeutics in the U.S. District Court for the Southern District of California. The complaint alleges that the company made materially false and misleading statements regarding changes to its statistical analysis plan for Deramiocel without FDA agreement, creating significant regulatory approval risks. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 can join the lawsuit, with a lead plaintiff deadline of September 28, 2026.